timothy sykes logo
DataMeds AI MEDS Stock Soars On Helomics Deal And GLP‑1 App Thumbnail
G Google News

DataMeds AI MEDS Stock Soars On Helomics Deal And GLP‑1 App

JACK KELLOGG•UPDATED OCT. 1, 2026, 7:48 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

DataMeds AI Inc. surged as new FDA-approved diagnostic AI platform headlines fueled bullish sentiment; stocks have been trading up by 39.12 percent

Key Takeaways

  • Completion of the Helomics AI cancer‑lab acquisition gives MEDS a CLIA/CAP‑certified facility, contracts, and $1.5M in cash on top of a $1.5M stock‑and‑note deal.
  • After the Helomics close, MEDS ripped roughly 300%–305% on extraordinary volume, signaling intense momentum trading interest.
  • Litigation tied to the 2023 Wellgistics deal was settled, wiping out about $19M in liabilities and retiring 364,099 shares for a $450,000 cash payment.
  • The “Health Lives Here” GLP‑1 app launch with Tollo Health sparked a 22.5%–39% surge in MEDS on heavy trading volume.
  • DataMeds AI is knitting together EinsteinRx AI, PharmacyChain blockchain, Helomics, and NFL Alumni Health marketing into a broad AI‑driven health IT platform.

Candlestick Chart

Live Update At 07:47:33 EDT: On Thursday, October 01, 2026 DataMeds AI Inc. stock [NASDAQ: MEDS] is trending up by 39.12%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

DataMeds AI Inc. (MEDS) is trading like a rollercoaster, and the fundamentals explain why traders are glued to the tape. The daily chart shows MEDS exploding from $0.87 on 2026/09/14 to an intraday high of $12.31 on 2026/09/16, right after the Helomics acquisition news. Since then, the stock has pulled back into the $3–$4 range, a classic post‑spike digestion zone that short‑term traders know well.

Under the hood, MEDS is still an early‑stage, cash‑burn story. Revenue over the last period was about $23.3M, but margins are deeply negative, with EBITDA around -$16.4M and net income near -$18.4M. Return on assets is sharply negative, and free cash flow was roughly -$3.1M. The balance sheet shows only about $2.5M in cash and a very weak current ratio near 0.1, meaning near‑term obligations far exceed liquid assets.

More Breaking News

For traders, that mix — fast top‑line, heavy losses, tight liquidity — usually translates into high volatility, frequent capital raises, and outsized moves on every headline. MEDS is being priced on story and catalysts more than on current profits, so charts and news flow matter as much as the income statement.

Why Traders Are Watching MEDS Right Now

MEDS has suddenly become one of those story stocks that momentum traders love. The trigger was the Helomics deal. DataMeds AI completed the $1.5M acquisition of Helomics, an AI‑driven cancer diagnostics and contract research lab, and in return also picked up $1.5M in cash, a CLIA/CAP‑certified lab, equipment, and active contracts — with no third‑party debt beyond normal operating expenses. That is a rare small‑cap structure: net cash plus assets, without dragging along legacy payables.

The market noticed. After MEDS closed on Helomics, shares spiked more than 300%–305% on extraordinary volume. For short‑term traders, that kind of move says one thing: this ticker is now on every momentum scanner. Intraday data shows MEDS ripping from the $3s into the $5s premarket, with wide 5‑minute candles between 06:00 and 07:30, then fading as profit‑takers stepped in — textbook parabolic behavior.

At the same time, DataMeds AI is trying to clean up its story. The company settled litigation linked to the 2023 Wellgistics membership purchase, paying $450,000 in cash to wipe out roughly $19M in liabilities and retire 364,099 shares. For MEDS, that removes a legal overhang and simplifies the capital structure — something swing traders focus on when gauging future dilution risk.

On the growth side, the “Health Lives Here” app with Tollo Health is MEDS’ bet on the GLP‑1 boom. The app targets patients using GLP‑1 drugs, integrating telehealth, pharmacy access, nutrition, wearables data, and behavioral health. News of that launch pushed MEDS up about 22.5%–39% on heavy volume around 2026/09/28. The company plans to expand the platform into Long COVID and cancer, while tying it into EinsteinRx AI, PharmacyChain blockchain, the Helomics oncology lab, and a planned multi‑party transaction with DataVault AI. Traders are effectively betting on MEDS as an AI‑driven health data and services platform, not a simple mail‑order pharmacy.

Conclusion

For active traders, MEDS is now a classic high‑beta catalyst play. The Helomics acquisition pushed DataMeds AI into oncology diagnostics and contract research, while adding cash and assets without piling on new third‑party debt. The Wellgistics settlement erased about $19M of liabilities and retired shares, reducing one major bearish talking point. Layer on the “Health Lives Here” GLP‑1 app pops and upcoming exposure at the 2026 National Telehealth and Virtual Care Summit, and you have steady news flow that can keep MEDS on watchlists.

At the same time, the financials show why MEDS remains speculative. Margins are deeply negative, cash is tight, and working capital is heavily underwater. That combination means dilution and financing risk stay front and center, even as the AI and oncology story gains traction. MEDS is trading on expectations — about Helomics scaling, AI models driving higher‑margin services, and the GLP‑1 and Long COVID ecosystems growing.

This is exactly the kind of setup Tim Sykes talks about: “Hot sector + big news + crazy volume can create huge opportunities, but only if you respect the volatility and cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”. DataMeds AI fits that description. For traders studying MEDS, the edge comes from tracking the chart, understanding the balance‑sheet constraints, and treating every spike as a trading vehicle — not a guarantee of long‑term success.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”